Chronic myeloproliferative neoplasms and risk of osteoporotic fractures; a nationwide population-based cohort study

Sarah Farmer, E. Puhó, Hanne Vestergaard, Anne Pernille Hermann, Henrik Frederiksen

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Patients with systemic mastocytosis have an increased risk of osteoporosis, however, the risk of osteoporotic fractures among the classic chronic myeloproliferative neoplasms (CMPN), including essential thrombocythaemia (ET), polycythaemia vera (PV) and chronic myeloid leukaemia (CML), is unknown. We conducted a population-based cohort study to determine the risk of osteoporotic fractures among three cohorts of patients with newly diagnosed ET, PV, and CML. Patients were identified in medical registers including all Danish hospitals during 1980-2010 and were followed until first osteoporotic fracture. Fracture risk was compared to cohorts from the general population matched on age, sex and calendar year. We followed 7595 CMPN patients and 338 974 comparison cohort members. We found that the risk of femoral fracture after 5 years was consistently higher than the general population, being 3·01% (95% confidence interval (CI): 2·20-4·10), 4·74% (95%CI: 4·06-5·52) and 4·64% (95%CI: 3·29-6·53) among ET, PV, and CML patients respectively. Adjusted hazard ratio for femoral fracture was increased 1·19-fold (95% CI: 0·94-1·51) for ET patients, 1·82-fold (95% CI: 1·62-2·04) for PV patients, and 2·67-fold (95% CI: 1·97-3·62) for CML patients. We conclude that CMPN patients are at higher risk of osteoporotic fractures than the general population.

Original languageEnglish
Pages (from-to)603-610
Number of pages8
JournalBritish Journal of Haematology
Volume163
Issue number5
DOIs
Publication statusPublished - Dec 2013

Fingerprint

Osteoporotic Fractures
Cohort Studies
Essential Thrombocythemia
Polycythemia Vera
Confidence Intervals
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Population
Neoplasms
Femoral Fractures
Systemic Mastocytosis
Osteoporosis

Keywords

  • Chronic myeloid leukaemia
  • Epidemiology
  • Essential thrombocythaemia
  • Osteoporosis
  • Polycythaemia vera

ASJC Scopus subject areas

  • Hematology

Cite this

Chronic myeloproliferative neoplasms and risk of osteoporotic fractures; a nationwide population-based cohort study. / Farmer, Sarah; Puhó, E.; Vestergaard, Hanne; Hermann, Anne Pernille; Frederiksen, Henrik.

In: British Journal of Haematology, Vol. 163, No. 5, 12.2013, p. 603-610.

Research output: Contribution to journalArticle

Farmer, Sarah ; Puhó, E. ; Vestergaard, Hanne ; Hermann, Anne Pernille ; Frederiksen, Henrik. / Chronic myeloproliferative neoplasms and risk of osteoporotic fractures; a nationwide population-based cohort study. In: British Journal of Haematology. 2013 ; Vol. 163, No. 5. pp. 603-610.
@article{1205e3db24684f6bbe3ff39091234af1,
title = "Chronic myeloproliferative neoplasms and risk of osteoporotic fractures; a nationwide population-based cohort study",
abstract = "Patients with systemic mastocytosis have an increased risk of osteoporosis, however, the risk of osteoporotic fractures among the classic chronic myeloproliferative neoplasms (CMPN), including essential thrombocythaemia (ET), polycythaemia vera (PV) and chronic myeloid leukaemia (CML), is unknown. We conducted a population-based cohort study to determine the risk of osteoporotic fractures among three cohorts of patients with newly diagnosed ET, PV, and CML. Patients were identified in medical registers including all Danish hospitals during 1980-2010 and were followed until first osteoporotic fracture. Fracture risk was compared to cohorts from the general population matched on age, sex and calendar year. We followed 7595 CMPN patients and 338 974 comparison cohort members. We found that the risk of femoral fracture after 5 years was consistently higher than the general population, being 3·01{\%} (95{\%} confidence interval (CI): 2·20-4·10), 4·74{\%} (95{\%}CI: 4·06-5·52) and 4·64{\%} (95{\%}CI: 3·29-6·53) among ET, PV, and CML patients respectively. Adjusted hazard ratio for femoral fracture was increased 1·19-fold (95{\%} CI: 0·94-1·51) for ET patients, 1·82-fold (95{\%} CI: 1·62-2·04) for PV patients, and 2·67-fold (95{\%} CI: 1·97-3·62) for CML patients. We conclude that CMPN patients are at higher risk of osteoporotic fractures than the general population.",
keywords = "Chronic myeloid leukaemia, Epidemiology, Essential thrombocythaemia, Osteoporosis, Polycythaemia vera",
author = "Sarah Farmer and E. Puh{\'o} and Hanne Vestergaard and Hermann, {Anne Pernille} and Henrik Frederiksen",
year = "2013",
month = "12",
doi = "10.1111/bjh.12581",
language = "English",
volume = "163",
pages = "603--610",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Chronic myeloproliferative neoplasms and risk of osteoporotic fractures; a nationwide population-based cohort study

AU - Farmer, Sarah

AU - Puhó, E.

AU - Vestergaard, Hanne

AU - Hermann, Anne Pernille

AU - Frederiksen, Henrik

PY - 2013/12

Y1 - 2013/12

N2 - Patients with systemic mastocytosis have an increased risk of osteoporosis, however, the risk of osteoporotic fractures among the classic chronic myeloproliferative neoplasms (CMPN), including essential thrombocythaemia (ET), polycythaemia vera (PV) and chronic myeloid leukaemia (CML), is unknown. We conducted a population-based cohort study to determine the risk of osteoporotic fractures among three cohorts of patients with newly diagnosed ET, PV, and CML. Patients were identified in medical registers including all Danish hospitals during 1980-2010 and were followed until first osteoporotic fracture. Fracture risk was compared to cohorts from the general population matched on age, sex and calendar year. We followed 7595 CMPN patients and 338 974 comparison cohort members. We found that the risk of femoral fracture after 5 years was consistently higher than the general population, being 3·01% (95% confidence interval (CI): 2·20-4·10), 4·74% (95%CI: 4·06-5·52) and 4·64% (95%CI: 3·29-6·53) among ET, PV, and CML patients respectively. Adjusted hazard ratio for femoral fracture was increased 1·19-fold (95% CI: 0·94-1·51) for ET patients, 1·82-fold (95% CI: 1·62-2·04) for PV patients, and 2·67-fold (95% CI: 1·97-3·62) for CML patients. We conclude that CMPN patients are at higher risk of osteoporotic fractures than the general population.

AB - Patients with systemic mastocytosis have an increased risk of osteoporosis, however, the risk of osteoporotic fractures among the classic chronic myeloproliferative neoplasms (CMPN), including essential thrombocythaemia (ET), polycythaemia vera (PV) and chronic myeloid leukaemia (CML), is unknown. We conducted a population-based cohort study to determine the risk of osteoporotic fractures among three cohorts of patients with newly diagnosed ET, PV, and CML. Patients were identified in medical registers including all Danish hospitals during 1980-2010 and were followed until first osteoporotic fracture. Fracture risk was compared to cohorts from the general population matched on age, sex and calendar year. We followed 7595 CMPN patients and 338 974 comparison cohort members. We found that the risk of femoral fracture after 5 years was consistently higher than the general population, being 3·01% (95% confidence interval (CI): 2·20-4·10), 4·74% (95%CI: 4·06-5·52) and 4·64% (95%CI: 3·29-6·53) among ET, PV, and CML patients respectively. Adjusted hazard ratio for femoral fracture was increased 1·19-fold (95% CI: 0·94-1·51) for ET patients, 1·82-fold (95% CI: 1·62-2·04) for PV patients, and 2·67-fold (95% CI: 1·97-3·62) for CML patients. We conclude that CMPN patients are at higher risk of osteoporotic fractures than the general population.

KW - Chronic myeloid leukaemia

KW - Epidemiology

KW - Essential thrombocythaemia

KW - Osteoporosis

KW - Polycythaemia vera

UR - http://www.scopus.com/inward/record.url?scp=84887615220&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887615220&partnerID=8YFLogxK

U2 - 10.1111/bjh.12581

DO - 10.1111/bjh.12581

M3 - Article

VL - 163

SP - 603

EP - 610

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 5

ER -